STE Insider Filing: Options and 487 RSUs Granted to Director Feldmann
Rhea-AI Filing Summary
In this Form 4 filing STERIS director Cynthia L. Feldmann reports a sale and new equity awards. On 08/11/2025 she sold 3,495 ordinary shares at a weighted-average price of $241.56, after which she holds 705 shares directly. The filing shows 8,663 ordinary shares held indirectly in the Cynthia L. Feldmann Revocable Trust. The report also records equity grants: on 08/08/2025 a director stock option to buy 1,407 shares at a $242.85 exercise price (exercisable immediately, expiring 08/08/2035) and 487 Career Restricted Stock Units that are fully vested and will be settled in ordinary shares six months after cessation of Board service. A director stock option with a $114.74 exercise price and 3,495 underlying shares is also listed with an exercisable date shown as 08/09/2028. The form is signed by an authorized representative on 08/12/2025.
Positive
- Equity awards granted: Director stock option for 1,407 shares at $242.85 (exercisable immediately) and 487 Career RSUs are recorded.
- Full vesting disclosed: The Career RSUs are noted as fully vested and will be settled in ordinary shares six months after cessation of Board service.
Negative
- Insider sale: The reporting person sold 3,495 ordinary shares on 08/11/2025 at a weighted-average price of $241.56.
- Reduced direct holdings: Following the sale the filing reports only 705 shares held directly by the reporting person.
Insights
TL;DR: Insider sale of 3,495 shares and concurrent option/RSU awards were reported; transactions are disclosed clearly with specific prices and dates.
The Form 4 documents a direct sale of 3,495 shares at a weighted-average $241.56 on 08/11/2025, reducing direct holdings to 705 shares. Separately, the filing records grant of a director option for 1,407 shares at $242.85 (exercisable immediately) and 487 Career RSUs that are fully vested and settle six months after board service ends. The filing provides a clear breakdown of direct and indirect holdings including 8,663 shares in a revocable trust. From a disclosure and reporting standpoint, material facts are presented precisely.
TL;DR: Equity grants appear tied to director service and retention; sale reduced direct holdings while trust ownership remains significant.
The filing shows compensation-style equity activity: immediate exercisable options and fully vested Career RSUs, which typically serve retention and alignment purposes. The reporting person’s direct stake falls to 705 shares after the sale, while the Cynthia L. Feldmann Revocable Trust holds 8,663 shares indirectly, both disclosed explicitly. All transactions include dates, prices and exercisability or settlement terms where applicable, meeting customary governance disclosure expectations.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Director Stock Option (right to buy) | 3,495 | $0.00 | -- |
| Exercise | Ordinary Shares | 3,495 | $0.00 | -- |
| Sale | Ordinary Shares | 3,495 | $241.56 | $844K |
| Grant/Award | Director Stock Option (right to buy) | 1,407 | $0.00 | -- |
| Grant/Award | Career Restricted Stock Units | 487 | $0.00 | -- |
| holding | Ordinary Shares | -- | -- | -- |
Footnotes (1)
- Price reflects a weighted average sale price for multiple transactions ranging from $241.38 to $241.705 per share, inclusive. The Reporting Person undertakes to provide, upon request by the SEC Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. These ordinary shares are held in the Cynthia L. Feldmann Revocable Trust, with Ms. Feldmann and her husband as Trustees. These nonqualified stock options are fully vested and are exercisable immediately. Each Career Restricted Stock Unit represents the right to receive one STERIS ordinary share six months after the cessation of the Director's Board service. These Career Restricted Stock Units are fully vested immediately. They will be settled in STERIS ordinary shares six months after the cessation of the Director's Board service.
